Toric IOL selection

Article

Dr Kermani discusses recent results of a retrospective analysis of three different lenses and how selection of an appropriate toric IOL can be made according to a patient's reading habits

In his presentation during the Multifocals I session, Dr Kermani revealed the results of a retrospective analysis of operations he and his colleagues (Drs Georg Gerten and Uwe Oberheide) performed on 52 eyes. In total three different IOLs were implanted in the study group who had a mean age of 60 years. The patients spherical aberration ranged from +9 to -13 D and the cylinder aberration was up to -7 D. Follow-up of the patients was performed in a three month interval and in over 90% of the group.

"At the 3-month follow-up, 85% of the patients implanted with the ReSTOR toric IOL gained at least one line or more," said Dr Kermani. The clinicians also found that two-thirds of Groups I and II had a post-op uncorrected near VA of J2 or better, just over half of the ReSTOR group achieved this.

"In an overview of the vector analysis of the total astigmatism, we found that the effective reduction of the total cylinder was from -2.25 D preoperatively to -0.75 D postoperatively," he added.

Additionally, Dr Kermani and colleagues noted that Group I and Group II achieved the best reading abilities while Group III had the best intermediate and distance VA results.

Extremely satisfying surgery

"So, we believe these kinds of surgery are extremely satisfying for the patients because pre-op uncorrected VA in both refractive lens exchange and cataract surgery is usually very poor," said Dr Kermani. "Therefore, the acceptance and efficacy of these IOLs are very high."

He concluded, "The end power of the mIOL determines the outcome with regards to the predominant near, intermediate or distance VA and hence selection can be made with respect to patients' viewing habits."

Special Contributor

Dr Omid Kermani is a consultant at the Augenklinik am Neumarkt, Augenlaserzentrum Köln, Germany, and a member of OTEurope's EAB. He can be reached by Email: o.kermani@augenportal.de

Dr Kermani has indicated no financial interests in the subject matter of this article.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.